NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
NanoViricides (NYSE: NNVC), a clinical-stage company focused on developing broad-spectrum antivirals using host-mimetic nanomedicine technology, has announced its participation in the D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. Company President & Executive Chairman Anil R. Diwan will be available for one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.
NanoViricides (NYSE: NNVC), un'azienda in fase clinica specializzata nello sviluppo di antivirali ad ampio spettro mediante tecnologia nanomedicina mimetica dell'ospite, ha annunciato la sua partecipazione al D. Boral Capital Inaugural Global Conference. L'evento si svolgerà il 14 maggio 2025 presso il The Plaza Hotel di New York City. Il Presidente e Executive Chairman dell'azienda, Anil R. Diwan, sarà disponibile per incontri individuali dalle 9:00 alle 15:00 (ET). Gli interessati possono fissare appuntamenti contattando John Perez all'indirizzo jperez@dboralcapital.com.
NanoViricides (NYSE: NNVC), una empresa en etapa clínica enfocada en desarrollar antivirales de amplio espectro utilizando tecnología de nanomedicina mimética del huésped, ha anunciado su participación en la D. Boral Capital Inaugural Global Conference. El evento se llevará a cabo el 14 de mayo de 2025 en The Plaza Hotel en la ciudad de Nueva York. El Presidente y Director Ejecutivo de la compañía, Anil R. Diwan, estará disponible para reuniones individuales de 9:00 a.m. a 3:00 p.m. (ET). Las partes interesadas pueden programar reuniones contactando a John Perez en jperez@dboralcapital.com.
NanoViricides (NYSE: NNVC)는 숙주 모방 나노의학 기술을 활용한 광범위 항바이러스제 개발에 중점을 둔 임상 단계 기업으로, D. Boral Capital Inaugural Global Conference에 참여한다고 발표했습니다. 행사는 2025년 5월 14일 뉴욕시의 The Plaza Hotel에서 개최됩니다. 회사의 사장 겸 집행 의장인 Anil R. Diwan은 오전 9시부터 오후 3시(동부 시간)까지 1:1 미팅에 참석할 예정입니다. 관심 있는 분들은 jperez@dboralcapital.com의 John Perez에게 연락하여 미팅을 예약할 수 있습니다.
NanoViricides (NYSE : NNVC), une société en phase clinique spécialisée dans le développement d'antiviraux à large spectre utilisant la technologie de nanomédecine mimétique de l'hôte, a annoncé sa participation à la D. Boral Capital Inaugural Global Conference. L'événement aura lieu le 14 mai 2025 au The Plaza Hotel à New York. Le président et président exécutif de la société, Anil R. Diwan, sera disponible pour des réunions individuelles de 9h00 à 15h00 (heure de l'Est). Les personnes intéressées peuvent organiser des rendez-vous en contactant John Perez à jperez@dboralcapital.com.
NanoViricides (NYSE: NNVC), ein klinisch fortgeschrittenes Unternehmen, das sich auf die Entwicklung breit wirkender antiviraler Mittel mittels wirtssimulierung basierender Nanomedizintechnologie spezialisiert hat, hat seine Teilnahme an der D. Boral Capital Inaugural Global Conference angekündigt. Die Veranstaltung findet am 14. Mai 2025 im The Plaza Hotel in New York City statt. Der Präsident und Executive Chairman des Unternehmens, Anil R. Diwan, steht für Einzelgespräche von 9:00 bis 15:00 Uhr (ET) zur Verfügung. Interessenten können Meetings vereinbaren, indem sie John Perez unter jperez@dboralcapital.com kontaktieren.
- None.
- None.
Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Anil R. Diwan, President & Executive Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET).
To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.
About NanoViricides
The Company has developed a novel broad-spectrum antiviral drug, NV-387, that can treat many unrelated viral infections and could be as revolutionary as the development of penicillin to treat many bacterial infections. NV-387, has completed Phase I human clinical trial successfully. The Company is preparing an application for a Phase II human efficacy clinical trial of NV-387 for the treatment of MPox in African region. Additional clinical trials for RSV, Influenza, COVID and other respiratory infections are planned. NV-387 is expected to be active for treatment of Measles virus infection as well. Additionally, the Company has developed NV-HHV-1, a drug for treatment of almost all herpesvirus infections, and NV-HIV-1 for treatment of HIV/AIDS. The Company's technology uniquely enables drugs that the virus cannot escape from, despite constant changes in the virus that have stymied traditional antibodies vaccines and small therapeutics approaches. The overall market size for the above three products alone is in the range of
About D. Boral Capital
D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, Middle East, and Latin America.
D. Boral Capital is a leader on Wall Street, having aggregated over
For further information:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
Source NanoViricides, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250560
FAQ
What is the purpose of NanoViricides (NNVC) participating in the D. Boral Capital Conference 2025?
When and where is NanoViricides (NNVC) presenting at the D. Boral Capital Conference?
Who will represent NanoViricides (NNVC) at the D. Boral Capital Conference 2025?
How can investors schedule meetings with NanoViricides (NNVC) management at the conference?
